Event: Thursday, July 30, 2026, before market open; earnings call at 9:00 a.m. ET. (ir.labcorp.com)
Investor focus: Whether Labcorp can sustain the Q1 combination of solid Diagnostics organic growth, high-margin specialty mix, Central Laboratory momentum, and margin expansion—while retaining room to raise full-year guidance again.
Published consensus calls for $3.71 billion of revenue and adjusted EPS of $4.79, implying approximately 5.2% revenue growth and 10.1% adjusted-EPS growth versus 2Q25’s $3.53 billion and $4.35, respectively. (marketbeat.com)
| Metric | 2Q26 consensus | 2Q25 actual | Implied YoY |
|---|---|---|---|
| Revenue | $3.71B | $3.53B | +5.2% |
| Adjusted EPS | $4.79 | $4.35 | +10.1% |
The stock closed July 29 at $310.28, up roughly 20.8% from the April 30 close following the first-quarter release. That means the bar is likely higher than a simple EPS beat: investors will want confirmation that full-year organic growth, margins, and cash generation remain at least as strong as the outlook established in April. At the current price, shares trade at roughly 17.2x the midpoint of management’s $17.70–$18.35 FY26 adjusted-EPS guidance.
Labcorp exited 1Q with tangible momentum:
The core question is not whether 2Q growth remains positive—it should—but whether the mix and operating leverage are sufficient to support another upward revision or at least create confidence around the upper half of the existing ranges.
Diagnostics is the largest earnings driver. Q1 organic revenue growth of 2.9% was held back by roughly $15 million of adverse weather, with organic volume estimated closer to 2% excluding that effect. A normalized 2Q comparison should therefore benefit from easier operational conditions.
Most important will be the composition of growth:
At the June Jefferies conference, management characterized Diagnostics’ full-year revenue mix as approximately 50/50 volume and price/mix, and said esoteric testing now represents about 40% of Diagnostics revenue. That reinforces the importance of mix-led growth and margin progression rather than simply chasing test volumes.
BLS is the swing factor for upside. Q1 was strong operationally, led by Central Labs, but the reported quarterly book-to-bill of 0.94 attracted attention. Management argued it was primarily timing-related, noted that trailing-12-month book-to-bill remained healthy at 1.04, and specifically expected a sequential improvement in 2Q.
For the report, investors should focus on:
Central Labs’ mix is especially valuable: it is the faster-growing and more profitable component of BLS, and management expects BLS margin expansion to exceed that of Diagnostics in 2026.
Labcorp’s Q1 adjusted operating margin expanded 40 bps year over year to 14.4%. The company’s full-year outlook assumes margin improvement in both segments, with BLS expanding faster due to Central Labs growth and Early Development actions.
Key items to assess:
One caveat: adjusted results exclude sizable recurring items such as amortization, acquisition/disposition costs, LaunchPad costs, and restructuring. The market will focus on adjusted EPS, but the trajectory of those excluded costs remains relevant to GAAP earnings quality.
The stock’s recent run makes full-year guidance the likely primary determinant of the post-print reaction.
After Q1, management guided to:
| FY26 outlook | Current range |
|---|---|
| Enterprise revenue | $14.65B–$14.80B |
| Enterprise revenue growth | 5.0%–6.1% |
| Diagnostics growth | 5.1%–5.9% |
| BLS growth | 3.8%–5.4% |
| Adjusted EPS | $17.70–$18.35 |
| Free cash flow | $1.24B–$1.36B |
The EPS midpoint is $18.03, while the revenue midpoint is $14.73 billion. A raise would likely require not only a beat, but sustained Diagnostics mix, evidence that BLS bookings recovered as indicated, and confidence in second-half free-cash-flow conversion.
A maintained outlook should not automatically be viewed negatively: management’s guide already embeds roughly 10% adjusted-EPS growth at the midpoint. However, following the Q1 raise and a 20%+ share-price appreciation since then, merely reiterating guidance without strong underlying KPI commentary may be insufficient.
Risks - PAMA / reimbursement policy: Labcorp has flagged uncertainty around the PAMA reporting process and potential 2027 reimbursement impacts. The company has advocated for the RESULTS Act; the eventual effect depends substantially on hospital and other laboratory participation in reporting. - ACA exchange utilization: Management still assumes roughly a 30 bp 2026 Diagnostics-volume headwind from ACA-related dynamics, although Q1’s realized impact was immaterial. - Specialty-test reimbursement: Oncology and MRD testing are strategically important, but reimbursement remains uneven in some indications. - BLS bookings volatility: A second consecutive sub-1.0 quarterly book-to-bill would challenge the timing explanation given after Q1. - M&A integration and capital deployment: Hospital/outreach laboratory acquisitions support growth but create execution, integration, and amortization costs.
Offsets - Health-system and regional-lab deal flow remains robust. - Higher test-per-accession and specialty mix can drive margin faster than revenue. - BLS backlog provides revenue visibility. - Free cash flow is seasonally weighted to the second half, leaving substantial opportunity for cash conversion after Q1’s low base.
Constructive heading into the print, but expectations are no longer low. Labcorp has a credible setup for a solid 2Q: normalized Diagnostics volumes after Q1 weather, sustained specialty and consumer momentum, Central Labs growth, and completion of Early Development actions. Consensus appears aligned with management’s broader FY26 framework rather than demanding a dramatic acceleration.
For the stock, the most favorable outcome would be: a revenue/EPS beat, Diagnostics organic growth led by specialty mix, a sequential recovery in BLS book-to-bill, continued segment-margin expansion, and either a guidance raise or commentary that clearly points to the upper half of the existing ranges. Conversely, weak Diagnostics volume, another soft BLS booking metric, or a cautious guide framework would matter more than a modest headline EPS beat.